What is Inhibrx Biosciences, Inc.'s stock-based comp?

Inhibrx Biosciences, Inc. (INBX) reported stock-based comp of $2.65M in Q1 2026.

How has Inhibrx Biosciences, Inc.'s stock-based comp changed year-over-year?

Inhibrx Biosciences, Inc.'s stock-based comp increased by 8.3% year-over-year, from $2.45M to $2.65M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Inhibrx Biosciences, Inc. INBX Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

Rogers CorporationROG

$1.7M-52.8%

Merck & Co.MRK

$185M-5.1%

Gilead SciencesGILD

$218M+4.3%

Nuvation BioNUVB

$9.03M+15.0%

ArriVent BioPharma, Inc.AVBP

$5.49M+142%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s stock-based comp?: Inhibrx Biosciences, Inc. (INBX) reported stock-based comp of $2.65M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s stock-based comp changed year-over-year?: Inhibrx Biosciences, Inc.'s stock-based comp increased by 8.3% year-over-year, from $2.45M to $2.65M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.